Cabenuva
Cabenuva
Cabenuva is a 2-drug co-packaged product of cabotegravir and rilpivirine. It is indicated as a complete regimen for the treatment of HIV-1 infection in adults and adolescents 12 years of age and older and weighing at least 35kg to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA <50 copies/mL) with no history of treatment failure.
It is an IV infusion once weekly for 4 weeks. It is given over 1 hour with a 1 hour observation period after the infusion.
The most common adverse reactions (≥ 10%) in patients treated with gMG are: respiratory tract infections, headache, and urinary tract infection.
In clinical trials, participants achieved significant improvements with daily activities (68% of patients) and a reduction in muscle weakness (63% of patients) when Vyvgart was added to current gMG treatment.
Administration Information
Cabenuva is an injection that can be given monthly or every 2 months depending on your medical providers’ recommendation.
Potential Side Effects
The most common side effects of CABENUVA include:
● pain, tenderness, lump, swelling, redness, itching, bruising, and warmth at the injection site
● Fever, tiredness, headache, muscle or bone pain, nausea, sleep problems, dizziness, rash
Helpful Resources
Patient Forms
Before you attend your first appointment at Omega Health, please make sure to review the documents below. The Patient Consent Form and HIPAA Privacy Authorization Form need to be filled out and signed ahead of your appointment, whereas the Notice of Privacy Practices and Patient Rights and Responsibilities are for reference only. Please contact us if you have any questions!
Patient Consent Form
Print & Sign
HIPAA Privacy Authorization Form
Print & Sign
Notice of Privacy Practice
Read
Patient Rights and Responsibilities
Read
Appointment Lateness and Cancelation
Read
